A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Condition: Refractory B-cell Acute Lymphoblastic Leukemia Intervention: Drug: Mosunetuzumab Sponsors: M.D. Anderson Cancer Center; Genentech, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Leukemia | Research | Study